

Open Peer Review on Qeios

Idelalisib/Rituximab Regimen

National Cancer Institute

Source

National Cancer Institute. <u>Idelalisib/Rituximab Regimen</u>. NCI Thesaurus. Code C160530.

A regimen consisting of idelalisib and rituximab that may be used in the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Qeios ID: 593TU9 · https://doi.org/10.32388/593TU9